Mesenchymal Stem/Stromal Cells in Immunity and Disease: A Better Understanding for an Improved Use
Abstract
:Author Contributions
Funding
Conflicts of Interest
References
- Najar, M.; Bouhtit, F.; Melki, R.; Afif, H.; Hamal, A.; Fahmi, H.; Merimi, M.; Lagneaux, L. Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges. J. Clin. Med. 2019, 8, 626. [Google Scholar] [CrossRef] [Green Version]
- Laroye, C.; Gauthier, M.; Antonot, H.; Decot, V.; Reppel, L.; Bensoussan, D. Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton’s Jelly, an Extraembryonic Source. J. Clin. Med. 2019, 8, 2207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Iacobaeus, E.; Kadri, N.; Lefsihane, K.; Boberg, E.; Gavin, C.; Törnqvist Andrén, A.; Lilja, A.; Brundin, L.; Blanc, K.L. Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis—A Phase I Study. J. Clin. Med. 2019, 8, 2102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Velier, M.; Simoncini, S.; Abellan, M.; Francois, P.; Eap, S.; Lagrange, A.; Bertrand, B.; Daumas, A.; Granel, B.; Delorme, B.; et al. Adipose-Derived Stem Cells from Systemic Sclerosis Patients Maintain Pro-Angiogenic and Antifibrotic Paracrine Effects In Vitro. J. Clin. Med. 2019, 8, 1979. [Google Scholar] [CrossRef] [Green Version]
- Buyl, K.; Merimi, M.; Rodrigues, R.M.; Moussa Agha, D.; Melki, R.; Vanhaecke, T.; Bron, D.; Lewalle, P.; Meuleman, N.; Fahmi, H.; et al. The Impact of Cell-Expansion and Inflammation on The Immune-Biology of Human Adipose Tissue-Derived Mesenchymal Stromal Cells. J. Clin. Med. 2020, 9, 696. [Google Scholar] [CrossRef] [Green Version]
- Voisin, C.; Cauchois, G.; Reppel, L.; Laroye, C.; Louarn, L.; Schenowitz, C.; Sonon, P.; Poras, I.; Wang, V.; Carosella, E.D.; et al. Are the Immune Properties of Mesenchymal Stem Cells from Wharton’s Jelly Maintained during Chondrogenic Differentiation? J. Clin. Med. 2020, 9, 423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elango, J.; Rahman, S.U.; Henrotin, Y.; de Val, J.E.M.S.; Bao, B.; Wang, S.; Li, B.; Wu, W. Parathyroid Hormone-Related Protein (PTHrP) Accelerates Soluble RANKL Signals for Downregulation of Osteogenesis of Bone Mesenchymal Stem Cells. J. Clin. Med. 2019, 8, 836. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ising, R.; Weinhold, S.; Bennstein, S.B.; Zimmermann, A.; Degistirici, Ö.; Kögler, G.; Meisel, R.; Hengel, H.; Timm, J.; Uhrberg, M. HCMV Infection in a Mesenchymal Stem Cell Niche: Differential Impact on the Development of NK Cells versus ILC3. J. Clin. Med. 2020, 9, 10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Behm, C.; Blufstein, A.; Gahn, J.; Kubin, B.; Nemec, M.; Moritz, A.; Rausch-Fan, X.; Andrukhov, O. 1,25(OH)2D3 Differently Affects Immunomodulatory Activities of Mesenchymal Stem Cells Depending on the Presence of TNF-α, IL-1β and IFN-γ. J. Clin. Med. 2019, 8, 2211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zarriello, S.; Neal, E.G.; Kaneko, Y.; Borlongan, C.V. T-Regulatory Cells Confer Increased Myelination and Stem Cell Activity after Stroke-Induced White Matter Injury. J. Clin. Med. 2019, 8, 537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Behnke, J.; Kremer, S.; Shahzad, T.; Chao, C.-M.; Böttcher-Friebertshäuser, E.; Morty, R.E.; Bellusci, S.; Ehrhardt, H. MSC Based Therapies—New Perspectives for the Injured Lung. J. Clin. Med. 2020, 9, 682. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crippa, S.; Santi, L.; Bosotti, R.; Porro, G.; Bernardo, M.E. Bone Marrow-Derived Mesenchymal Stromal Cells: A Novel Target to Optimize Hematopoietic Stem Cell Transplantation Protocols in Hematological Malignancies and Rare Genetic Disorders. J. Clin. Med. 2020, 9, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Batsali, A.K.; Georgopoulou, A.; Mavroudi, I.; Matheakakis, A.; Pontikoglou, C.G.; Papadaki, H.A. The Role of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles (MSC-EVs) in Normal and Abnormal Hematopoiesis and Their Therapeutic Potential. J. Clin. Med. 2020, 9, 856. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sava, R.I.; Pepine, C.J.; March, K.L. Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy. J. Clin. Med. 2020, 9, 241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, Y.; Yamamoto, Y.; Xiao, Z.; Ochiya, T. The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity. J. Clin. Med. 2019, 8, 1025. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alfaro, D.; Rodríguez-Sosa, M.R.; Zapata, A.G. Eph/ephrin Signaling and Biology of Mesenchymal Stromal/Stem Cells. J. Clin. Med. 2020, 9, 310. [Google Scholar] [CrossRef] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Merimi, M.; Lagneaux, L.; Agha, D.M.; Lewalle, P.; Meuleman, N.; Burny, A.; Fahmi, H.; Najar, M. Mesenchymal Stem/Stromal Cells in Immunity and Disease: A Better Understanding for an Improved Use. J. Clin. Med. 2020, 9, 1516. https://doi.org/10.3390/jcm9051516
Merimi M, Lagneaux L, Agha DM, Lewalle P, Meuleman N, Burny A, Fahmi H, Najar M. Mesenchymal Stem/Stromal Cells in Immunity and Disease: A Better Understanding for an Improved Use. Journal of Clinical Medicine. 2020; 9(5):1516. https://doi.org/10.3390/jcm9051516
Chicago/Turabian StyleMerimi, Makram, Laurence Lagneaux, Douâa Moussa Agha, Philippe Lewalle, Nathalie Meuleman, Arsène Burny, Hassan Fahmi, and Mehdi Najar. 2020. "Mesenchymal Stem/Stromal Cells in Immunity and Disease: A Better Understanding for an Improved Use" Journal of Clinical Medicine 9, no. 5: 1516. https://doi.org/10.3390/jcm9051516